Pharming Group N.V. - ADR Forecast, price target & analysts
Pharming Group N.V. - ADR Target price 2026 - Analyst rating & recommendation
Pharming Group N.V. - ADR Classifications & Recommendation
Pharming Group N.V. - ADR Price Target
| Target Price | $2.40 |
| Price | $9.53 |
| Deviation |
74.79%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Pharming Group N.V. - ADR 2027 .
The average Pharming Group N.V. - ADR target price is $2.40.
This is
74.79%
register free of charge
$2.88
69.73%
register free of charge
$2.04
78.61%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Pharming Group N.V. - ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2027 of
74.79%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 376.13 | 408.22 |
| 26.56% | 8.53% | |
| EBITDA Margin | 11.56% | 7.52% |
| 361.15% | 34.95% | |
| Net Margin | 0.76% | 6.70% |
| 119.02% | 784.24% |
7 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2026 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2026. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Pharming Group N.V. - ADR Analysts have issued a net profit forecast 2026. The average Pharming Group N.V. - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.00 | 0.04 |
| 100.00% | ||
| P/E | 246.73 | |
| EV/Sales | 1.56 |
7 Analysts have issued a Pharming Group N.V. - ADR forecast for earnings per share. The average Pharming Group N.V. - ADR EPS is
This results in the following potential growth metrics and future valuations:
Pharming Group N.V. - ADR...
Current Pharming Group N.V. - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jul 12 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | May 08 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jul 12 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
May 08 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
May 07 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
